Money will cover a DNA manufacturing process, which will be used to test a flu vaccine.

The NIAID awarded a $136,000 phase 1 SBIR grant  to CytoGenix. The money will be used to develop a DNA vaccine against the flu. The grant is entitled “Novel DNA Manufacturing Process: Cell-Free Production and Testing of a New Multivalent DNA Vaccine Against Human Influenza (H5N1).”

Frederic Kendirgi, Ph.D., senior research scientist at the company, will be the principal investigator on the research. “Results from this grant may pave the way for a new generation of DNA vaccines against influenza virus strains using our synDNA production process which can be rapidly adapted to new viral strains,” comments Dr. Kendirgi.

Previous articleAxentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program
Next articleMillipore Completes $3.4M Expansion of Missouri Facility